March 4, 2020

Francis Collins, MD, PhD
Director, National Institutes of Health
Building 1
9000 Rockville Pike
Bethesda, MD 20892

Re: NIH Report on Postural Orthostatic Tachycardia Syndrome (POTS)

Dear Dr. Collins,

The undersigned researchers and clinicians write to you to express concern regarding the recent NIH report, “Postural Orthostatic Tachycardia Syndrome (POTS): State of the Science, Clinical Care, and Research” which you submitted to the House and Senate Appropriations Committees on January 31, 2020. We have concerns regarding the process NIH implemented to create the report. Additionally, there are several factual errors in the report, and the report fails to provide the information requested by Congress, which we consider essential to moving this field of research forward.

Concerns About The Process NIH Used to Create the Report

As you know, in the report accompanying the fiscal year (FY) 2019 appropriations for the Department of Health and Human Services, the Senate Committee on Appropriations stated, in pertinent part:

The Committee encourages NHLBI and NINDS to jointly host a symposium with participants from NIAID, NIDDK, NICHD and leading external researchers and stakeholders to examine the current state of POTS research. The Committee directs the NIH to provide a report to the House and Senate Committees on Appropriations 9 months after enactment of this act that reflects participants’ findings on: (1) the current state of POTS research; (2) priority areas of focus for future POTS research through 2025; (3) a summary of ongoing or upcoming efforts by NIH to advance the scientific understanding of POTS; and (4) an estimate of the level of funding that would be needed annually to achieve objectives (2) and (3). (Senate Reports 115-289, page 92) (emphasis added)

On July 29, 2019, 29 POTS experts from around the world gathered at the NIH offices in Bethesda, MD for the first-ever NIH research meeting on POTS. The group was eager to begin a conversation with NIH on the critical unmet needs in our field and exciting opportunities for new research that would allow us to deliver more effective treatments for millions of Americans living with POTS.

Unfortunately, the resulting NIH report does not reflect the findings of the meeting participants as directed by Congress. The report was written by NIH staff who, respectfully, have little to no expertise in POTS.
The meeting chairs, Satish Raj, MD, MSCI and Steven Vernino, MD, PhD, were the only meeting participants allowed to see a draft of the report prepared by NIH staff. A majority of the substantive edits provided by the meeting chairs were disregarded by NIH staff and not incorporated into the final report. No response was ever provided by NIH staff to the edits the meeting chairs requested, nor did the meeting chairs see a final copy of the report before it was submitted to Congress. The first time the meeting chairs saw the final report was February 11, 2020, eleven days after the final report was submitted to Congress.

None of the other POTS expert meeting participants were given an opportunity to review or comment on the draft report, despite the fact that their names appear on it. Other POTS expert meeting participants requested the opportunity to review and comment on the draft, but their requests were denied by NIH staff.

A fair and transparent process aimed at meeting the Congressional directive to provide a report that included the participants’ findings would have allowed all of the POTS experts invited to the meeting adequate time to review and comment upon the report. If NIH staff disagreed with the POTS expert participants’ findings, NIH staff could have noted this in the report or in an accompanying letter. Instead, the perspectives of the POTS experts who lent their time and talents to the NIH for the purposes of this meeting were largely ignored.

**The Report Contains Several Factual Errors**
The report contains several factual errors that should be corrected by the NIH in an amended report. The patient community, the academic community, and the media is likely to cite this report in the future; therefore, NIH has an obligation to ensure that the report is factually accurate.

First, the report asserts that NIH is funding over $9.35M in POTS or related research. This is a grossly inflated number. Of the 14 studies included on the list prepared by NIH staff, only four of them are POTS or POTS related research studies, and one additional grant has a small portion of its funding related to POTS. In total, NIH is currently funding less than $2M in grants related to POTS (see attached spreadsheet). NIH staff ignored edits on the draft report from both meeting chairs seeking to correct this misinformation. This is discussed further below.

Second, the report implies there is serious disagreement amongst experts on the POTS diagnostic criteria, relabeling internationally accepted consensus criteria as “key features” rather than diagnostic criteria. There is no serious disagreement amongst a majority of experts on the POTS diagnostic criteria. The NIH minimized the significance of internationally accepted consensus criteria and ignored edits on the draft report from the meeting chairs seeking to correct this misinformation.

Third, the report falsely claims that chronic fatigue syndrome is the most common co-morbidity in POTS. This was not presented by any expert during the NIH meeting, nor does this appear anywhere in the POTS literature. NIH provides two citations to support this claim. Citation 7 is a 2000 study from Mayo Clinic that does not make any assessment or assertion regarding the percentage of POTS patients who have co-morbid chronic fatigue syndrome. Citation 8 confirms that migraine, irritable bowel syndrome and Ehlers-Danlos syndrome are more common co-morbidities in POTS than chronic fatigue syndrome. Throughout the literature and in clinical practices that serve a large POTS population, it is clear that small fiber neuropathy, migraine, autoimmunity, neurocardiogenic syncope and Ehlers-Danlos syndrome are all equally or more common than chronic fatigue syndrome in the POTS population. NIH staff ignored comments from the meeting chairs regarding the NIH’s over-emphasis of the relevance of chronic fatigue syndrome in the report.
Fourth, the report states that half of individuals diagnosed with POTS are children and adolescents. This was not asserted by any expert during the meeting, nor is this supported by the published data on POTS. About half of POTS patients develop POTS symptoms in adolescence, and half develop POTS symptoms in adulthood.\(^1\) A majority of adolescent onset patients have not fully recovered by the time they reach adulthood,\(^2\) therefore a majority of individuals living with POTS are adults.

Fifth, the report claims “NIH investigators also have reported POTS in families who carry genetic mutations that cause increased production of alpha-tryptase.” NIH investigators did not report a genetic mutation. They reported on a few families who had duplicate copies of the alpha-tryptase gene, which is known to occur in about 5% of the general population.

Sixth, the report claims that “[p]hysicians also recommend that patients with POTS regularly check and track their blood pressure and pulse.” This was not stated by any of the experts during the meeting, and it is contrary to the advice that is given by most POTS experts to their patients. Regular monitoring of blood pressure and pulse is only recommended by clinicians to POTS patients in limited circumstances, such as when starting a new medication, or when beginning a new exercise regimen.

Seventh, the report states that structural studies of the autonomic nerves would be invasive and “unlikely to benefit patients.” The assertion that neuropathology studies are unlikely to benefit patients was never made during the expert meeting. In many autonomic labs, it is routine clinical practice to perform skin punch biopsies to screen for small fiber neuropathy in POTS patients. This benefits patients, because it can confirm the presence of small fiber neuropathy, providing validation for the patient, and leading to identification of a treatable underlying cause in some cases.

The Report Fails To Provide the Information Requested by Congress
Congress directed NIH to prepare a report that reflected the meeting participants’ findings on four objectives:

1. the current state of POTS research;
2. priority areas of focus for future POTS research through 2025;
3. a summary of ongoing or upcoming efforts by NIH to advance the scientific understanding of POTS; and
4. an estimate of the level of funding that would be needed annually to achieve objectives (2) and (3).

Objective 1
The report barely achieves objective 1. There has been 25 years of research progress in understanding POTS, but the report only includes a three-page summary. Outdated studies are cited throughout the report. A majority of the study findings POTS experts presented during the meeting were not mentioned or cited in the report.

Objective 2
The report broadly describes eight priority areas for future research. This is the one part of the report that seems to have met the objective.


Objective 3
As noted above, the report grossly exaggerates NIH’s ongoing efforts to advance the scientific understanding of POTS by including millions of dollars in research funding that has nothing to do with POTS in the report.

NIH staff completely disregarded edits requested by the meeting chairs, who advised NIH staff that most of the funding on the list was not related to POTS whatsoever.

The items in **bold** in this table were presented in the NIH report as part of “Table 1 - Active NIH Funding for Projects on POTS and Related Research” (NIH POTS Report, page 15). The items in *red italics* are the actual numbers, as determined by the meeting chairs and other POTS experts who carefully reviewed each project NIH included in the report.

**Table 1. Active NIH Funding for Projects on POTS and Related Research**

<table>
<thead>
<tr>
<th>NIH ICO</th>
<th>Number of projects claimed to be POTS related by NIH</th>
<th>Number of POTS related projects determined by POTS experts</th>
<th>Active POTS Related Funding Claimed by NIH</th>
<th>Active POTS Related Funding determined by POTS experts</th>
</tr>
</thead>
<tbody>
<tr>
<td>NHGRI</td>
<td>1</td>
<td>1</td>
<td>$166,235</td>
<td>$166,235</td>
</tr>
<tr>
<td>NHLBI</td>
<td>5</td>
<td>3</td>
<td>$2,270,230</td>
<td>$1,588,514</td>
</tr>
<tr>
<td>NIDCD</td>
<td>1</td>
<td>NONE</td>
<td>$511,179</td>
<td>NONE</td>
</tr>
<tr>
<td>NICHD</td>
<td>1</td>
<td>NONE</td>
<td>$400,541</td>
<td>NONE</td>
</tr>
<tr>
<td>NINDS</td>
<td>4</td>
<td>NONE</td>
<td>$4,783,993</td>
<td>NONE</td>
</tr>
<tr>
<td>Office of the Director</td>
<td>2</td>
<td>NONE</td>
<td>$1,226,406</td>
<td>NONE</td>
</tr>
<tr>
<td><strong>Totals</strong></td>
<td><strong>14</strong></td>
<td><strong>4</strong></td>
<td><strong>$9,358,584</strong></td>
<td><strong>$1,754,749</strong></td>
</tr>
</tbody>
</table>

Detailed comments on the relevance or non-relevance of each study listed by NIH can be found on the attached spreadsheet.

For example, NIH claimed an NINDS intramural study, Biomarkers of Catecholaminergic Degeneration, is a POTS related study. However, the study is about neurodegenerative disorders like Parkinson’s and multiple system atrophy, diseases that occur in the elderly that have nothing to do with POTS. The meeting chairs pointed out this error to NIH staff, but their requested edits were ignored.

In addition to exaggerating the amount of funds NIH is spending on POTS or POTS related research, the report offers no information on upcoming efforts by NIH to advance the scientific understanding of POTS between 2020 and 2025. In fact, all of the POTS related grants cited by NIH expire by 2023.

Objective 4
The report completely fails to address objective 4. No estimate of the level of funding needed to achieve objectives 2 and 3 is provided.

While the report was supposed to reflect the participants’ findings on the amount of funding needed to achieve the research objectives, NIH staff told the POTS expert speakers prior to the meeting that they were not allowed to recommend or even mention dollar amounts needed to fund the research priorities identified. There was no time on the agenda developed by NIH staff allocated to discussing what POTS research NIH was already funding, or the funding needed to achieve the priority areas identified by the meeting participants.
The report states “NIH is committed to sustained funding in order to advance research on POTS.” Again, this is not what Congress asked the NIH to report on. Congress asked NIH to report the participants’ findings regarding the top research priorities until 2025, and how much it would cost to fund those priorities. Moreover, sustained funding of $2M per year is insufficient to properly study even one of the eight priority areas mentioned in the report.

**Conclusion**

We urge the NIH to prepare a revised report with input from the meeting chairs and other POTS experts that offers Congress more accurate information on POTS, an accurate assessment of NIH’s active POTS research funding, specific priority areas for future research, and the funding necessary to achieve those objectives by 2025.

Sincerely,

Satish Raj, MD, MSCI, FACC  
NIH POTS Meeting Co-Chair  
President, American Autonomic Society  
Professor of Cardiac Sciences  
University of Calgary

Steven Vernino, MD, PhD  
NIH POTS Meeting Co-Chair  
President Elect, American Autonomic Society  
Distinguished Teaching Professor & Vice Chair  
Department of Neurology & Neurotherapeutics  
University of Texas Southwestern

Hasan Abdallah, MD, FAAP, FACC, FSCAI  
Medical Director  
The Children’s Heart Institute

Amy C. Arnold, PhD  
Assistant Professor  
Department of Neural & Behavioral Sciences  
Penn State College of Medicine  
Adjunct Assistant Professor  
Division of Clinical Pharmacology & Autonomic Dysfunction Center  
Vanderbilt University Medical Center

Jonas Axelsson, MD, PhD  
Associate Professor  
Department of Clinical Immunology  
Medical Director, Center for Apheresis and Stem Cell Handling  
Karolinska University Hospital  
Clinical Research Center  
Lund University

Roy L. Freeman, MD  
Professor of Neurology  
Director, Center for Autonomic and Peripheral Nerve Disorders  
Harvard Medical School

Brent Goodman, MD  
Assistant Professor of Neurology  
Director, Autonomic Laboratory  
Mayo Clinic

Blair P. Grubb, MD  
Distinguished University Professor of Medicine and Pediatrics  
Director, Clinical Cardiac Electrophysiology  
Director, Clinical Autonomic Disorders Center  
University of Toledo Medical Center

Mitchell Miglis, MD  
Clinical Assistant Professor  
Neurology and Neurological Sciences, Autonomic Division  
Psychiatry and Behavioral Sciences, Sleep Medicine Division  
Stanford University

Amanda J. Miller, PhD  
Postdoctoral Fellow  
Department of Neural and Behavioral Sciences  
Pennsylvania State University College of Medicine

Jeffrey P. Moak, MD  
Director, Electrophysiology and Pacing  
Department of Cardiology  
Children’s National Health System
Italo O. Biaggioni, MD
Professor of Medicine and Pharmacology
David Robertson, MD Professorship in Autonomic Disorders
Director, Vanderbilt Autonomic Dysfunction Center
Vanderbilt University Medical Center

Jeffrey Boris, MD
Pediatric Cardiologist

Kamal R. Chémali, MD
Associate Professor of Neurology
Eastern Virginia Medical School
Medical Director, Sentara Autonomic and Neuromuscular Center
Sentara Healthcare

Tae Chung, MD
Assistant Professor of PM&R and Neurology
Director, Johns Hopkins POTS Clinic Program
Johns Hopkins University

Melissa M. Cortez, DO
Assistant Professor of Neurology
Director, Autonomic Laboratory
University of Utah

André Diedrich, MD, PhD
Research Professor of Medicine and Biomedical Engineering
Vanderbilt Autonomic Dysfunction Center
Vanderbilt University Medical Center

Taylor Doherty, MD, FAAAAI
Associate Professor
Section Chief, Allergy and Immunology
Department of Medicine
University of California, San Diego
Staff Physician, Allergy and Immunology
VA San Diego Health System

Artur Fedorowski MD, PhD, FESC
Associate Professor
Dept. of Clinical Sciences
Lund University
Senior Consultant, Syncope Unit
Dept. of Cardiology
Skåne University Hospital

Laura A. Pace, MD, PhD
Assistant Professor
Department of Internal Medicine, Division of Gastroenterology
Director, Neurogastroenterology Clinic
Co-Director, Multidisciplinary Ehlers-Danlos Syndromes Clinic
University of Utah Adult Co-Lead, NIH Undiagnosed Diseases Network
Center for Genomic Medicine, University of Utah

Peter C. Rowe, MD
Professor
Department of Pediatrics
Sunshine Natural Wellbeing Foundation Professor of Chronic Fatigue and Related Disorders
Johns Hopkins University School of Medicine

Robert S. Sheldon, MD, PhD
Professor of Cardiac Sciences, Medicine and Medical Genetics
Libin Cardiovascular Institute of Alberta
University of Calgary

Cyndya Shibao, MD, MSCI, FAHA, FAAS
Associate Professor
Department of Medicine
Division of Clinical Pharmacology
Vanderbilt Autonomic Dysfunction Center
Vanderbilt University Medical Center

Julian Stewart, MD, PhD
Professor of Pediatrics, Physiology and Medicine
Director, Center for Hypotension
New York Medical College

Lauren Stiles, JD
President, Dysautonomia International
Research Assistant Professor of Neurology
Stony Brook University School of Medicine

David M. Systrom, MD
Assistant Professor
Pulmonary & Critical Care Medicine
Director, Advanced Cardiopulmonary Exercise Testing Program
Harvard Medical School
cc: Hon. Senator Roy Blunt
    Hon. Senator Patty Murray
    Hon. Representative Rosa DeLauro
    Hon. Representative Tom Cole
    Members of the Senate Appropriations Committee, Subcommittee on Labor, Health and Human Services, Education and Related Agencies
    Members of the House Appropriations Committee, Subcommittee on Labor, Health and Human Services, Education and Related Agencies

Enc.
<table>
<thead>
<tr>
<th>Study Title and Citation in NIH Reporter</th>
<th>Short Description</th>
<th>Lead PI</th>
<th>Grant Number</th>
<th>Project End Date</th>
<th>Total NIH Claimed</th>
<th>POTS Related?</th>
<th>Relevant POTS Funding</th>
</tr>
</thead>
</table>